##  [State Medical Products Administration Announces Protected Variety of Traditional Chinese Medicine (China)](/index%2ephp/mandate/state-medical-products-administration-announces-protected-variety-of-traditional-chinese-medicine-china) 

October 9, 2025

The National Medical Products Administration (NMPA) of China approved Heilongjiang Auridanonide Pharmaceutical Co., Ltd.’s bezoar Qinggan capsules as the first second-level protected variety of traditional Chinese medicine. The protection period is seven years from the date of the announcement. Key highlights include: · Announcement Details: Titled “Announcement on Protected Varieties of Traditional Chinese Medicine (No. 31) (No. 97 of 2025)”, released on 09-Oct-2025. · Protected Variety Information: Bezoar Qinggan capsules assigned protection number ZYB2072025029. · Protection Period: Seven years starting from the announcement date. · Authority: Released by the State Food and Drug Administration on 29-Sep-2025. Freyr can help companies understand and navigate protected TCM varieties, manage intellectual property compliance, and plan regulatory strategies for innovative traditional medicine products in China.



[Consult Now](/webform/consult?url=https://preprod.freyrsolutions.com/index%2ephp/mandate/state-medical-products-administration-announces-protected-variety-of-traditional-chinese-medicine-china)



Select Mandate HA

[NMPA](/index%2ephp/mandate-by-ha/nmpa)

 

Select Mandate Function

[Country Regulatory Affairs](/index%2ephp/mandate-by-function/country-regulatory-affairs)